Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Kathleen Cooney

GU Oncology · Duke

View

Dr. Kimryn Rathmell

GU Oncology · Arthur G James Cancer Hospital

View

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Julia Close

General Oncology · UF

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Allison Fitzgerald

General Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Rebecca Miksad

GI Oncology · BMC

View

Dr. Lee Scheinbart

General Oncology · Burrell College of Osteopathic Medicine

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    PPDr. Patrick Pilie
    Leading Voice

    Dr. Patrick Pilie

    Medical Oncology · Genitourinary Oncology
    The University of Texas MD Anderson Cancer Center
    patrickp

    Research

    iGTP: Learning Interpretable Cellular Embedding for Inferring Biological Mechanisms Underlying Single-Cell Transcriptomics

    2025

    Via Briefings in Bioinformatics

    Research

    CHIMERA-DDR: A Machine Learning Framework for Classifying Heterogeneous Mismatch-Repair and Homologous-Recombination Deficiency Patterns in Prostate Cancer

    2025

    Via bioRxiv

    Research

    iGTP: Learning interpretable cellular embedding for inferring biological mechanisms underlying single-cell transcriptomics

    2025

    Via Briefings in Bioinformatics

    Research

    Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial

    2025

    Via European Urology

    Research

    Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone Therapy

    2025

    Via JCO Oncology Practice

    Research

    A Phase II Trial of Apalutamide for Intermediate-Risk Prostate Cancer and Molecular Correlates

    2024

    Via BJU International

    Research

    Body Composition as a Determinant of the Therapeutic Index with Androgen Signaling Inhibition

    2024

    Via Prostate Cancer and Prostatic Diseases

    Research

    Body Composition in Recurrent Prostate Cancer and the Role of Steroidogenic Genotype

    2024

    Via Endocrine-Related Cancer

    Research

    scEMB: Learning Context Representation of Genes Based on Large-Scale Single-Cell Transcriptomics

    2024

    Via bioRxiv

    Research

    Targeting ATR in patients with cancer

    2024

    Via Nature Reviews Clinical Oncology

    Research

    Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

    2024

    Via Clinical Cancer Research

    Research

    A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer

    2024

    Via Clinical Cancer Research

    Research

    A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates

    2024

    Via BJU International

    Research

    Body composition as a determinant of the therapeutic index with androgen signaling inhibition

    2024

    Via Prostate Cancer and Prostatic Diseases

    Research

    Body composition in recurrent prostate cancer and the role of steroidogenic genotype

    2024

    Via Endocrine-related cancer